1. Home
  2. Live Updates
  3. Editorpicks2

Live Breaking News & Updates on Editorpicks2

Stay informed with the latest breaking news from Editorpicks2 on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Editorpicks2 and stay connected to the pulse of your community

Brazil's 'Covaxingate' Investigation Closes in on Bolsonaro and Bharat Biotech

As the vaccine scandal reached the doorstep of Jair Bolsonaro, a Brazil senate panel is considering unlocking the fiscal records of Madison Biotech, owned by Bharat Biotech.

Brasilia , Distrito-federal , Brazil , India , Singapore , Brazilian , Bharat , Omar-aziz , Sphaera-pharma , Randolfe-rodrigues , Precisa-medicamentos , Raches-ella

Centre Signs Deal With Vaccine Maker Biological-E, Reserves 300 Million Doses

The RBD protein sub-unit vaccine, which is currently undergoing phase-3 clinical trials, is likely to be available in the next few months, the health ministry said in a statement.

Hindustan , India-general , India , Canada , New-delhi , Delhi , Canadian , Narendra-modi , Mahima-datla , Johnson , Providence-therapeutics-holdings , Research-institute-translational-health-science-technology

Mumbai's COVID Situation Is Improving – but Is the City Safe From More Surges?


Mumbai's COVID Situation Is Improving – but Is the City Safe From More Surges?
Remarkably, the total number of infections Mumbai has seen since the pandemic began may be approaching the total number of residents in the city.
A man suffering from COVID-19 receives oxygen support as he sits inside the classroom of a school turned into a COVID-19 care facility on the outskirts of Mumbai, May 24, 2021. Photo: REUTERS/Francis Mascarenhas
Rights9 hours ago
A boy suffering from COVID-19 stands outside his room at a school-turned care facility on the outskirts of Mumbai, May 24, 2021. Photo: Reuters/Francis Mascarenhas
Mumbai’s current COVID-19 wave is not over. But the city is in a much better position than it was six weeks ago. The case-load has fallen steadily. Daily cases averaged under 1,300 during the week ending May 24, just 13% of peak values in early April.

Mumbai , Maharashtra , India , United-kingdom , Murad-banaji , Francis-mascarenhas , Google , Astrazeneca-vaccine , B-1-617 , B-1-617-2 , Coronavirus , Covid-19

Why India Must Speak Up Against the New Pandemic Treaty Proposal at the WHO


Why India Must Speak Up Against the New Pandemic Treaty Proposal at the WHO
A framework convention is not the correct type of legal instrument with which to resolve the WHO's structural and financial issues.
WHO director general Tedros Adhanom Ghebreyesus attends a news conference at the United Nations in Geneva, Switzerland on May 18, 2018. Photo: Denis Balibouse/Reuters
World2 hours ago
A decision regarding the launch of negotiations of a ‘New Pandemic Treaty’ is expected to take place at the 74th World Health Assembly (WHA74), happening this week. The European Union (EU) and several other member-states are pushing for the assembly to make a quick decision on the proposal, which will create a ‘Global Framework Convention on Pandemic Preparedness and Response’ (see the EU policy statement here). The negotiations are bound to be hectic.

India , Russia , Brazil , Tedros-adhanom-ghebreyesus , World-health-assembly , International-health-regulations , Advisory-committee , Pfizer , Astrazeneca , Global-framework-convention-on-pandemic-preparedness , European-union , Johnson

Sunderlal Bahuguna Blew the Bugle. Will We Heed It and Save Ourselves?


Sunderlal Bahuguna Blew the Bugle. Will We Heed It and Save Ourselves?
The author remembers a chance meeting in August 2010 with the Gandhian environmentalist alongside the Ganga.
Sunderlal Bahuguna. Photo: Twitter/@kuljitnagra1
Government2 hours ago
On May 21, 2021, I found out through a social media post that Sunderlal Bahunguna had passed away in Rishikesh. He had tested positive for COVID-19 three days earlier. I had only recently thought of him when multiple dead bodies were found floating on the Ganga, the river for whose preservation Bahuguna had dedicated his lifelong activism.
I thought of his forlorn eyes that held the Ganga in them, as I had witnessed up close one evening more than a decade ago.

Alaknanda-river , India-general , India , Gangotri , Uttaranchal , Tehri , Uttarakhand , Bhagirathi-river , Garhwal , Rudraprayag , China , Russia

COVID-19 Vaccine Expansion Will Not Begin on May 1 in These States

At least 15 states and one union territory have confirmed that people between the ages of 18 and 44 will have to wait before they can take the shot.

Jammu , Jammu-and-kashmir , India , Madhya-pradesh , Mumbai , Maharashtra , Karnataka , New-delhi , Delhi , Pune , Tamil-nadu , Suriname

Harsh Vardhan and SII Statements Keep Covishield Price Confusion Alive


Harsh Vardhan and SII Statements Keep Covishield Price Confusion Alive
The health minister asserted that the Centre would continue to procure the vaccine candidate at Rs 150 per dose, even as the Pune-based company claimed that it would be sold at Rs 400.
Men ride on a motorbike past a supply truck of India's Serum Institute, the world's largest maker of vaccines, in Pune, May 2020. Photo: Reuters/Euan Rocha
Health7 hours ago
New Delhi: The Union health minister’s assertion that the two locally produced COVID-19 vaccine candidates – Covishield and Covaxin – will continue to be procured at Rs 150 per dose by the Centre, as well as the Serum Institute of India (SII)’s failure to clarify the issue specifically, continues to keep alive the issue of differential pricing for state governments.

India , New-delhi , Delhi , Pune , Maharashtra , Bharat , Bharat-biotech , Harsh-vardhan , Adar-poonawalla , Union-territories , Serum-institute-of-india , Serum-institute

Covishield Will Be Rs 400 for State Govts, Rs 600 in Private Hospitals: Serum Institute


Covishield Will Be Rs 400 for State Govts, Rs 600 in Private Hospitals: Serum Institute
The Pune-based SII said it will address its limited capacity by scaling up the vaccine production over the next two months.
A health worker holds a vial with doses of Covishield in Paramaribo, Suriname, February 23, 2021. Photo: Reuters/Ranu Abhelakh
Health8 hours ago
New Delhi: The Serum Institute of India (SII) announced on Wednesday that its Covishield vaccine candidate would be sold at a price of Rs 600 per dose to private hospitals and Rs 400 per dose to state governments.
The announcement comes two days after the Centre liberalised India’s vaccination drive against COVID-19, allowing state governments to directly approach manufacturers to procure doses and allowing anybody over the age of 18 to get vaccinated from May 1.

India , New-delhi , Delhi , Pune , Maharashtra , Seruminstituteindia-seruminstindia , Twitter , Serum-institute-of-india , Serum-institute , Adar-poonawalla , Covid-19 , Covid-19-vaccine-drive

India Reports Just Under 90,000 Daily COVID-19 Cases


India Reports Just Under 90,000 Daily COVID-19 Cases
The death toll increased by 714, the highest since October 21. The jump in cases reported on Saturday was the highest since September 20 last year.
A vaccination camp of MGF Toyota for employees and their family members, April 2, 2021. Photo: PTI
Health03/Apr/2021
New Delhi: India on Saturday recorded 89,129 new daily COVID-19 cases, the highest daily rise in around six-and-half-months, taking the nationwide tally of infections to over 1.23 crore, according to the Union health ministry data on Saturday.
The death toll increased to 1,64,110 with 714 more fatalities in a day, also the highest since October 21.
The jump in cases reported on Saturday was the highest since September 20 last year, when 92,605 new infections were recorded in a span of 24 hours.

India , New-delhi , Delhi , Union-territories , Indian-council-of-medical-research , Indian-council , Medical-research , Rajiv-gauba , Corona-virus , Covid-19 , Covid-19-cases

Is 'Atmanirbhar Bharat' Holding Up India's Genome Sequencing Program?


Is 'Atmanirbhar Bharat' Holding Up India's Genome Sequencing Program?
India's newly launched programme to widely and rapidly sequence genomes of the novel coronavirus has already run into major hurdles.
Illustration: ColiN00B/pixabay
Bengaluru: Rakesh Mishra, the director of Hyderabad’s Centre for Cellular and Molecular Biology (CCMB), is frustrated. CCMB has been sequencing SARS-CoV-2 viral genomes since the COVID-19 pandemic began – initially as part of its own research program and since December 2020 as part of the Indian SARS-CoV-2 Genomics Consortium (INSACOG), a group of ten labs the government put together to ramp up sequencing across to India.
To do its work, Mishra’s team needs specialised plastic containers and reagents that go into sequencing machines. But buying them has become needlessly complicated in the last year, taking time away from his lab’s core jobs, according to Mishra.

Yavatmal , Maharashtra , India , Karnataka , United-kingdom , New-delhi , Delhi , Pune , Amravati , Brazil , South-africa , Uttar-pradesh